What do metformin, Viagra and Avastin have in common? They are all used to treat conditions
besides those they were originally developed to treat. Drug repositioning, or repurposing,
describes the process of deploying therapeutics to new indications. The impetus to
find additional applications for currently prescribed drugs, as well as novel uses
for shelved compounds, is becoming increasingly important as the drug development
pipeline dwindles.
The crux of the problem is money. It typically takes over a decade and in excess of
a billion dollars to bring a drug to market. This imposes severe financial pressure
on the R&D departments of pharmaceutical companies and non-commercial entities embarking
on drug development. Failures that occur later on in the development process are particularly
expensive. The magnitude of the problem is difficult to ascertain, but a conservative
estimate is that < 10% of mature preclinical de novo compounds make it to product
launch. This attrition means that the majority of unsuccessful compounds are dropped
or stalled, never to be heard of again. Not only is this a costly and inefficient
process, but important data concerning drug safety profiles and synthesis are never
published, creating a black hole for valuable information.
While the notion of drug repositioning is not new, the drive to rescue compounds from
the brink of obscurity has gained momentum as a means to stimulate the currently flawed
drug development model. There are two forms of repositioning: drug-centered, whereby
promiscuous drugs act on more than one biological target (such as metformin which
activates AMPK in diabetes and a variety of molecular targets in cancer); and disease-centered,
in which diseases that share pathophysiological mechanisms can be affected by the
same drug (such as Viagra, which is used to treat erectile dysfunction and pulmonary
arterial hypertension by causing vasodilation via a reduction in cyclic guanosine
monophosphate degradation).
From a business standpoint, repositioning makes sense as a great deal of information
about the pharmacokinetics, toxicity and manufacture of a drug is already known. This
knowledge can offer an advantage over de novo drugs that have yet to pass these scientific
and regulatory barriers, translating to a shorter time to market and improved success
rate. However, there is an argument that resurrecting failed and abandoned compounds
might have a negative impact on scientific innovation and the pursuit of novel drugs.
This is true to some extent, but drugs can act in unexpected ways in new indications,
enabling a deeper understanding of a disease that can stimulate new avenues of research.
This was recently exemplified by the use of glitazones to treat chronic myeloid leukemia
(CML) as reported in Nature on September 2, 2015. These peroxisome proliferator-activated
receptor-γ agonists are traditionally used to treat diabetes, but Prost and colleagues
found that they were also able to target the CML leukemia stem cell pool, achieving
a complete molecular response in all CML patients tested.
Drug repurposing also provides the opportunity to foster collaboration between industry
and academia. This relationship is mutually beneficial: academic researchers are allowed
access to well-characterized, clinical-relevant compounds to test in new indications,
and the industrial partner potentially gains knowledge of new molecular targets, and
the etiology and pathophysiology of disease. At the recent 28th European College of
Neuropsychopharmacology (ECNP) Congress in Amsterdam, The Netherlands, David Nutt
gave a passionate talk about the Medicines Chest, an initiative whereby the ECNP acts
as broker between researchers and industry to provide pharmacological compounds for
human experimental medicine studies. So far, 23 pharmaceutical companies are on-board
with > 30 compounds in the chest.
This enterprise has been mirrored by similar efforts worldwide to unite stakeholders
committed to drug-repurposing. The UK Medical Research Council oversees the Industry
Asset Sharing Initiative in which seven industry partners offer deprioritized molecules
to research scientists. A recent success was AZD3355, a GABA-B receptor agonist, originally
used to treat gastro-esophageal reflux and repurposed to treat chronic cough. In the
United States, the National Center for Advancing Translational Sciences (NCATS) also
has a Repurposing Drugs Program that is divided into early-stage repurposing (high-throughput
screens of already approved compounds), and late-stage repurposing (regulatory–quality
data packages to support a drug's entry into clinical trials for new disease indication).
A recent achievement came from a partnership between NCATS-associated academic scientists
and AstraZeneca through the repurposing of saracatinib. Originally developed to treat
cancer, saracatinib was recently shown to restore brain function in mouse models of
Alzheimer's disease and entered a Phase 2a clinical trial within 18 months — a process
that would take up to a decade using an untested compound.
Despite these successes, repurposing drugs can be a controversial business. Pharmaceutical
companies can remove a perfectly active drug from one indication, reformulate it in
a minor way without any chemical alteration (for example modifying the dose or altering
the formulation), and rebrand it for a new indication at a substantially higher price.
Limiting the availability of the anti-cancer drug Avastin (bevacizumab) for wet age-related
macular degeneration (AMD) is a well-reported example, as it has comparable efficacy
(according to NIH's comparison of AMD treatments trials), and is far less costly than
the prescribed alternative Lucentis (ranibizumab). While some claim that off-label
use of bevacizumab to treat wet AMD is unsafe, many doctors feel this is a cynical
pharmaceutical maneuver that prioritizes profit ahead of patients. This debate is
ongoing and bevacizumab is not, at present, approved by the US Food and Drug Administration
or European Medicine Agency as a treatment for wet AMD.
Finding new uses for existing compounds makes financial and scientific sense even
though its implementation can be challenging. It is worth remembering that a unifying
need to improve disease treatment should prevail and that sometimes, contrary to the
old adage, you can teach an old dog new tricks.
EBioMedicine